Synthetic studies on the indane SHIP1 agonist AQX-1125

Otto M. Dungan; Shawn Dormann; Sandra Fernandes; Brian C. Duffy; Daniel G. Effiong; William G. Kerr; John D. Chisholm

doi:10.1039/d2ob00555g

Synthetic studies on the indane SHIP1 agonist AQX-1125

Otto M. Dungan, Shawn Dormann, Sandra Fernandes, Brian C. Duffy, Daniel G. Effiong, William G. Kerr, John D. Chisholm

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

AQX-1125 is an indane based SHIP1 agonist that has been evaluated in the clinic for the treatment of bladder pain syndrome/interstitial cystitis. To support our own studies on SHIP1 agonists as potential treatments for IBD and Crohn's disease, a new synthetic route to the SHIP1 agonist AQX-1125 has been developed. This sequence utilizes a hydroxy-acid intermediate which allows for ready differentiation of the C6 and C7 positions. The role of the C17 alkene in the biological activity of the system is also investigated, and this functional group is not required for SHIP1 agonist activity. While AQX-1125 shows SHIP1 agonist activity in enzyme assays, it does not show activity in cell based assays similar to other SHIP1 agonists, which limits the utility of this molecule.

Original language	English (US)
Pages (from-to)	4016-4020
Number of pages	5
Journal	Organic and Biomolecular Chemistry
Volume	20
Issue number	19
DOIs	https://doi.org/10.1039/d2ob00555g
State	Published - May 4 2022

ASJC Scopus subject areas

Biochemistry
Physical and Theoretical Chemistry
Organic Chemistry

Access to Document

10.1039/d2ob00555g

Cite this

@article{e28fdbdb90cc4307a1fc0fc9102410f7,

title = "Synthetic studies on the indane SHIP1 agonist AQX-1125",

abstract = "AQX-1125 is an indane based SHIP1 agonist that has been evaluated in the clinic for the treatment of bladder pain syndrome/interstitial cystitis. To support our own studies on SHIP1 agonists as potential treatments for IBD and Crohn's disease, a new synthetic route to the SHIP1 agonist AQX-1125 has been developed. This sequence utilizes a hydroxy-acid intermediate which allows for ready differentiation of the C6 and C7 positions. The role of the C17 alkene in the biological activity of the system is also investigated, and this functional group is not required for SHIP1 agonist activity. While AQX-1125 shows SHIP1 agonist activity in enzyme assays, it does not show activity in cell based assays similar to other SHIP1 agonists, which limits the utility of this molecule.",

author = "Dungan, {Otto M.} and Shawn Dormann and Sandra Fernandes and Duffy, {Brian C.} and Effiong, {Daniel G.} and Kerr, {William G.} and Chisholm, {John D.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Royal Society of Chemistry",

year = "2022",

month = may,

day = "4",

doi = "10.1039/d2ob00555g",

language = "English (US)",

volume = "20",

pages = "4016--4020",

journal = "Organic and Biomolecular Chemistry",

issn = "1477-0520",

publisher = "Royal Society of Chemistry",

number = "19",

}

TY - JOUR

T1 - Synthetic studies on the indane SHIP1 agonist AQX-1125

AU - Dungan, Otto M.

AU - Dormann, Shawn

AU - Fernandes, Sandra

AU - Duffy, Brian C.

AU - Effiong, Daniel G.

AU - Kerr, William G.

AU - Chisholm, John D.

PY - 2022/5/4

Y1 - 2022/5/4

N2 - AQX-1125 is an indane based SHIP1 agonist that has been evaluated in the clinic for the treatment of bladder pain syndrome/interstitial cystitis. To support our own studies on SHIP1 agonists as potential treatments for IBD and Crohn's disease, a new synthetic route to the SHIP1 agonist AQX-1125 has been developed. This sequence utilizes a hydroxy-acid intermediate which allows for ready differentiation of the C6 and C7 positions. The role of the C17 alkene in the biological activity of the system is also investigated, and this functional group is not required for SHIP1 agonist activity. While AQX-1125 shows SHIP1 agonist activity in enzyme assays, it does not show activity in cell based assays similar to other SHIP1 agonists, which limits the utility of this molecule.

AB - AQX-1125 is an indane based SHIP1 agonist that has been evaluated in the clinic for the treatment of bladder pain syndrome/interstitial cystitis. To support our own studies on SHIP1 agonists as potential treatments for IBD and Crohn's disease, a new synthetic route to the SHIP1 agonist AQX-1125 has been developed. This sequence utilizes a hydroxy-acid intermediate which allows for ready differentiation of the C6 and C7 positions. The role of the C17 alkene in the biological activity of the system is also investigated, and this functional group is not required for SHIP1 agonist activity. While AQX-1125 shows SHIP1 agonist activity in enzyme assays, it does not show activity in cell based assays similar to other SHIP1 agonists, which limits the utility of this molecule.

UR - http://www.scopus.com/inward/record.url?scp=85131455570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131455570&partnerID=8YFLogxK

U2 - 10.1039/d2ob00555g

DO - 10.1039/d2ob00555g

M3 - Article

AN - SCOPUS:85131455570

SN - 1477-0520

VL - 20

SP - 4016

EP - 4020

JO - Organic and Biomolecular Chemistry

JF - Organic and Biomolecular Chemistry

IS - 19

ER -

Synthetic studies on the indane SHIP1 agonist AQX-1125

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this